Solvias, one of the largest independent analytical testing, contract research, development, and manufacturing companies, today announced that it has acquired Canton, Mass.-based Chemic Laboratories, Inc. (Chemic). With this acquisition, Solvias gains a strong foothold in the United States and highly complementary laboratory testing capabilities.
Located in the biopharmaceutical hub of Boston, Chemic expands Solvias’ global presence and portfolio of integrated testing and analytical services. As one organization, Solvias, and Chemic:
- support 650+ pharmaceutical corporations, biotech businesses, emerging ATMP companies, as well as a medical device and cosmetics companies;
- operate nearly 225,000 square feet of laboratory space in Switzerland, France, and the United States in accordance with the highest industry standards, including ISO, cGMP, and GLP;
- offer an extensive suite of analytical services including chemical and physical characterization, quality control, microbiology, and cell biology testing and stability testing;
- provide combined areas of strengths in synthesis, catalysis, and extractable and leachable testing;
- employ more than 600 people possessing deep scientific and technical expertise, with a significant number holding advanced academic degrees.
Joseph St. Laurent, co-founder, president, and chief scientific officer, Chemic, said, “In the 20+ years we have grown Chemic, Solvias is the only organization we have encountered that shares our vision and has the team to build a world-renowned organization. Solvias is highly regarded for its scientific expertise, innovation, and outstanding customer service. Together, we share a deep-seated commitment to our clients and complementary scientific knowledge and analytical services on a global scale.”
Scott A. Goodrich, co-founder and site head, Chemic, added, “This is a great opportunity to further expand our offering in the Boston area, United States and beyond.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Chemic is Solvias’ first acquisition since partnering with health care investors Water Street Healthcare Partners and JLL Partners in June 2020 to strategically grow the company. Since then, Solvias has recruited industry leaders to join its board and commenced a program to significantly upgrade and expand its information technology platform and infrastructure in support of further global expansion plans. The company is pursuing organic investments and acquisitions to add specialized capabilities to support clients in the growing areas of biologics and cell & gene therapies.
Karen Huebscher, Ph.D., chief executive officer, Solvias, stated, “We are making great progress toward our goal of building Solvias into a global leader at the forefront of our industry. In a short amount of time, we have grown our teams, advanced organic initiatives, and completed a strategic acquisition. Our combination with Chemic provides us with an important presence in the United States and extends our scientific capabilities to meaningfully benefit our customers and our mission of helping them bring safer and better products to market faster.”
Chemic’s co-founders, Messrs. St. Laurent and Goodrich, will join Solvias’ leadership team and continue to lead operations in the United States. They also will continue to operate Chemic’s product development businesses as separate entities.
The financial terms of the acquisition are not being disclosed.
Source: Biospace
